Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Servier
Varian, a Siemens Healthineers Company
Eli Lilly and Company
Boehringer Ingelheim
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Montefiore Medical Center
Montefiore Medical Center
Travera Inc
University Health Network, Toronto
Alliance for Clinical Trials in Oncology
Fondazione del Piemonte per l'Oncologia
Fondazione del Piemonte per l'Oncologia
Turning Point Therapeutics, Inc.
Conjupro Biotherapeutics, Inc.
Abramson Cancer Center at Penn Medicine
Pfizer
Wake Forest University Health Sciences
Pfizer
Mayo Clinic
Centre Oscar Lambret
Centre Oscar Lambret
PMV Pharmaceuticals, Inc
Mayo Clinic
UMC Utrecht
Hoffmann-La Roche
University of California, Irvine
ViroMissile, Inc.
Hospices Civils de Lyon
Sichuan Enray Pharmaceutical Sciences Company
Washington University School of Medicine
Pfizer
Tizona Therapeutics, Inc
M.D. Anderson Cancer Center
Clasp Therapeutics, Inc.
OHSU Knight Cancer Institute
Baylor College of Medicine
University of Colorado, Denver
SystImmune Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
UNC Lineberger Comprehensive Cancer Center
Daiichi Sankyo
Grey Wolf Therapeutics
University of Nebraska
Zhejiang University
Kidney Cancer Research Bureau
Adela, Inc
Natera, Inc.
Second Life Therapeutics
M.D. Anderson Cancer Center